Vesilute: A Khavinson Dipeptide Bioregulator

Research summary. Vesilute is a short dipeptide (Glu-Asp) developed within the Khavinson "peptide bioregulator" research programme in St. Petersburg, Russia. Within that framework, it is described as having organotropic activity for the urinary bladder and prostate, with reported effects on smooth-muscle tone, microcirculation, and tissue homeostasis in genitourinary tissues. As with the wider Khavinson bioregulator family, the supporting literature is concentrated within the originating Russian research programme, and independent Western validation is limited. Researchers should treat reported effects as hypothesis-generating and weigh them against the broader replication landscape.

Molecular profile

• Sequence: Glu-Asp (EN; H-Glu-Asp-OH)
• Molecular formula: C₉H₁₄N₂O₇
• Molecular weight: ~262.2 g/mol
• Class: Khavinson short-chain peptide bioregulator (cytomedine family)
• Reported tissue tropism: Urinary bladder and prostate

Mechanism of action

The mechanistic framework proposed within the Khavinson research programme for short-chain bioregulators including Vesilute centres on:

• Direct DNA / chromatin interaction. Khavinson and colleagues have proposed that short peptides interact with specific DNA sequences and modulate gene expression in a tissue-specific manner.
• Tissue-specific gene-expression modulation. Within this framework, each bioregulator is reported to act preferentially on the tissue from which it was originally isolated — bladder and prostate tissue in the case of Vesilute.
• Reported smooth-muscle and microcirculatory effects. The Russian research programme reports relaxation of smooth muscle in the bladder wall and improvements in microcirculation in prostate tissue.

The general "short-peptide → DNA / gene-expression" model proposed for the Khavinson bioregulator class has not been broadly replicated outside the originating research programme, and standard pharmacology (receptor identification, structure–activity relationships, independent in vitro reproductions) is not well established for these short dipeptides and tripeptides.

Preclinical and applied research

Bladder and lower-urinary-tract function. Within the Khavinson programme, Vesilute has been reported to influence bladder smooth-muscle tone and to be of interest in age-related lower-urinary-tract conditions.

Prostate research. Reported effects on prostate microcirculation and tissue homeostasis are described within the same programme, with proposed relevance to age-related prostate enlargement.

Reproductive parameters. Russian research has reported effects of cytomedine peptides — including Vesilute — on sperm production and sperm quality in animal models.

Independent validation. Independent Western preclinical or clinical replication of these specific findings is limited. The Glu-Asp dipeptide has also been characterised in food-chemistry contexts (it is one of several umami-active dipeptides), which is unrelated to the bioregulator framework.

Current research status

Vesilute is not approved by any major Western regulator (FDA, EMA, MHRA) for any indication. It is supplied as a research-grade peptide where available and is not intended for self-administration. Researchers working with this peptide should approach it as an investigational research material, recognise the limited independent literature, and design experiments with appropriate vehicle controls and orthogonal endpoints.

Key takeaways for researchers

• Vesilute is a Glu-Asp dipeptide developed within the Khavinson bioregulator research programme.
• Within that framework, it is described as organotropic for bladder and prostate tissue, with reported effects on smooth-muscle tone and microcirculation.
• Supporting literature is concentrated in the originating Russian research programme; independent Western validation of the underlying mechanistic model is limited.
• It is not FDA-approved and is supplied as a research-grade peptide for laboratory use only.

References

1. Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger, 2005.
2. Khavinson VK, Linkova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2014;156(6):737–743.

---

This article is provided for educational and research purposes only. Vesilute is a research peptide. It is not currently FDA-approved and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. The supporting literature is concentrated in a single research programme and independent validation is limited. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.